Video

Increased Risk of Tardive Dyskinesia

Author(s):

John J. Miller, MD

How could drugs that block post-synaptic dopamine 2 receptors increase the risk for tardive dyskinesia over time?

John J. Miller, MD, talks about the increased risk of tardive dyskinesia on a synaptic level.

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
innovation
December 10th 2024

Psychopharmacology Innovations

John J. Miller, MD
tardive versus spontaneous dyskinesia
April 17th 2019

Not All That Writhes Is Tardive Dyskinesia

Chris Aiken, MD
How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.
June 5th 2024

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

Mehdi Farokhnia, MD, MPH
Rakesh Jain
June 3rd 2024

Why Clinicians Should Be Excited About Austedo XR

Leah Kuntz Rakesh Jain, MD, MPH
Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.
May 30th 2024

Research and Opportunities at the 2024 ASCP Annual Meeting

Erin Crown, MHS, PA-C
tardive dyskinesia
May 30th 2024

Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia and Huntington Disease

Leah Kuntz
© 2024 MJH Life Sciences

All rights reserved.